Search results
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Added:
2 years ago
In this interview, Dr Adam DeVore (Duke University School of Medicine, Durham, NC) discusses the key findings of the CONNECT-HF randomized clinical trial, which aimed to evaluate the gap between clinical trials and practice in the management of heart failure with reduced ejection fraction.
Questions:
What is the CONNECT-HF Trial, and what does it aim to address?
What is the design, patient…
View more
Added:
10 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Added:
1 year ago
In this short video we asked Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) about the key heart failure highlights of 2022 and his thoughts on what comes next in HF treatment and research.
Recorded at Heart Failure 2022, Madrid.
View more
Added:
1 year ago
In this short interview from HF 22, Prof Lars Lund (Karolinska Institute, Stockholm, SE) joins us on-site to discuss the outcomes of the Ghrelin-HF study. This was a placebo controlled, randomised trial that evaluated the effects of intravenous ghrelin in patients with heart failure with preserved ejection fraction (HFpEF).
Discussion Points:
Aims of This Study
Mechanism of Action
Patient…
View more
Added:
3 years ago
The history of documented heart failure in medical literature dates back as early as the late 1700s, when William Withering recognized the therapeutic use of foxglove in patients with “dropsy”. The extract from the foxglove plant contained the cardiac glycoside digitalis, and edema – known as “dropsy” – was described in patients we now presume had the clinical syndrome of heart failure.1 Over the…
View more
Start date:
Nov 15, 2022
View more
Added:
7 months ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principle investigator, Dr Divaka Perera (King’s College London & Guy’s & St Thomas’ Hospital, UK) and investigator, Dr Peter O'Kane (Royal Bournemouth Hospital, UK) to discuss the REVIVED-BCIS2 viability analysis (NCT01920048).
This analysis of the REVIVED-BICS2 trial found that viability…
View more
Added:
3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly…
View more
« First